ONCOCROSS

  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

  • oncoMASTER

CONTACT US
한
  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

  • oncoMASTER

  • 한
  • EN
CONTACT US
  • Main
  • News/IR
  • Press

머니투데이

"AI 방광암 항암 반응 예측 기술, 임상 적용 가능성 확인"

  • 05-19-2026
https://www.mt.co.kr/thebio/2026/05/19/2026051909175544983
Previous
온코크로스, 휴먼앤바이오와 혈관 조직 기반 AI 바이오마커 공동연구 05-21-2026
Next
온코크로스 "임상 데이터 기반 플랫폼 딜 본격화…亞 정밀의료 데이터 시장 선도" 04-27-2026
List

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
#905 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Korea
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.